

Currently released so far... 12478 / 251,287
Browse latest releases
2010/12/01
2010/12/02
2010/12/03
2010/12/04
2010/12/05
2010/12/06
2010/12/07
2010/12/08
2010/12/09
2010/12/10
2010/12/11
2010/12/12
2010/12/13
2010/12/14
2010/12/15
2010/12/16
2010/12/17
2010/12/18
2010/12/19
2010/12/20
2010/12/21
2010/12/22
2010/12/23
2010/12/24
2010/12/25
2010/12/26
2010/12/27
2010/12/28
2010/12/29
2010/12/30
2011/01/01
2011/01/02
2011/01/04
2011/01/05
2011/01/07
2011/01/09
2011/01/10
2011/01/11
2011/01/12
2011/01/13
2011/01/14
2011/01/15
2011/01/16
2011/01/17
2011/01/18
2011/01/19
2011/01/20
2011/01/21
2011/01/22
2011/01/23
2011/01/24
2011/01/25
2011/01/26
2011/01/27
2011/01/28
2011/01/29
2011/01/30
2011/01/31
2011/02/01
2011/02/02
2011/02/03
2011/02/04
2011/02/05
2011/02/06
2011/02/07
2011/02/08
2011/02/09
2011/02/10
2011/02/11
2011/02/12
2011/02/13
2011/02/14
2011/02/15
2011/02/16
2011/02/17
2011/02/18
2011/02/19
2011/02/20
2011/02/21
2011/02/22
2011/02/23
2011/02/24
2011/02/25
2011/02/26
2011/02/27
2011/02/28
2011/03/01
2011/03/02
2011/03/03
2011/03/04
2011/03/05
2011/03/06
2011/03/07
2011/03/08
2011/03/09
2011/03/10
2011/03/11
2011/03/13
2011/03/14
2011/03/15
2011/03/16
2011/03/17
2011/03/18
2011/03/19
2011/03/20
2011/03/21
2011/03/22
2011/03/23
2011/03/24
2011/03/25
2011/03/26
2011/03/27
2011/03/28
2011/03/29
2011/03/30
2011/03/31
2011/04/01
2011/04/02
2011/04/03
2011/04/04
2011/04/05
2011/04/06
2011/04/07
2011/04/08
2011/04/09
2011/04/10
2011/04/11
2011/04/12
2011/04/13
2011/04/14
2011/04/15
2011/04/16
2011/04/17
2011/04/18
2011/04/19
2011/04/20
2011/04/21
2011/04/22
2011/04/23
2011/04/24
2011/04/25
2011/04/26
2011/04/27
2011/04/28
2011/04/29
2011/04/30
Browse by creation date
Browse by origin
Embassy Athens
Embassy Asuncion
Embassy Astana
Embassy Asmara
Embassy Ashgabat
Embassy Apia
Embassy Ankara
Embassy Amman
Embassy Algiers
Embassy Addis Ababa
Embassy Accra
Embassy Abuja
Embassy Abu Dhabi
Embassy Abidjan
Consulate Auckland
Consulate Amsterdam
Consulate Adana
American Institute Taiwan, Taipei
Embassy Bujumbura
Embassy Buenos Aires
Embassy Budapest
Embassy Bucharest
Embassy Brussels
Embassy Bridgetown
Embassy Bratislava
Embassy Brasilia
Embassy Bogota
Embassy Bishkek
Embassy Bern
Embassy Berlin
Embassy Belmopan
Embassy Belgrade
Embassy Beirut
Embassy Beijing
Embassy Banjul
Embassy Bangkok
Embassy Bandar Seri Begawan
Embassy Bamako
Embassy Baku
Embassy Baghdad
Consulate Barcelona
Embassy Copenhagen
Embassy Conakry
Embassy Colombo
Embassy Chisinau
Embassy Caracas
Embassy Canberra
Embassy Cairo
Consulate Curacao
Consulate Ciudad Juarez
Consulate Chennai
Consulate Casablanca
Consulate Cape Town
Consulate Calgary
Embassy Dushanbe
Embassy Dublin
Embassy Doha
Embassy Djibouti
Embassy Dili
Embassy Dhaka
Embassy Dar Es Salaam
Embassy Damascus
Embassy Dakar
Consulate Dubai
Embassy Helsinki
Embassy Harare
Embassy Hanoi
Consulate Ho Chi Minh City
Consulate Hermosillo
Consulate Hamilton
Consulate Hamburg
Consulate Halifax
Embassy Kyiv
Embassy Kuwait
Embassy Kuala Lumpur
Embassy Kinshasa
Embassy Kingston
Embassy Kigali
Embassy Khartoum
Embassy Kathmandu
Embassy Kampala
Embassy Kabul
Consulate Kolkata
Embassy Luxembourg
Embassy Luanda
Embassy London
Embassy Ljubljana
Embassy Lisbon
Embassy Lima
Embassy Lilongwe
Embassy La Paz
Consulate Lahore
Consulate Lagos
Mission USOSCE
Mission USNATO
Mission UNESCO
Embassy Muscat
Embassy Moscow
Embassy Montevideo
Embassy Monrovia
Embassy Minsk
Embassy Mexico
Embassy Mbabane
Embassy Maputo
Embassy Manila
Embassy Manama
Embassy Managua
Embassy Malabo
Embassy Madrid
Consulate Munich
Consulate Mumbai
Consulate Montreal
Consulate Monterrey
Consulate Milan
Consulate Melbourne
Embassy Nicosia
Embassy Niamey
Embassy New Delhi
Embassy Ndjamena
Embassy Nassau
Embassy Nairobi
Consulate Naples
Consulate Naha
Embassy Pristina
Embassy Pretoria
Embassy Prague
Embassy Port Of Spain
Embassy Port Louis
Embassy Port Au Prince
Embassy Phnom Penh
Embassy Paris
Embassy Paramaribo
Embassy Panama
Consulate Peshawar
REO Basrah
Embassy Rome
Embassy Riyadh
Embassy Riga
Embassy Reykjavik
Embassy Rangoon
Embassy Rabat
Consulate Rio De Janeiro
Consulate Recife
Secretary of State
Embassy Suva
Embassy Stockholm
Embassy Sofia
Embassy Skopje
Embassy Singapore
Embassy Seoul
Embassy Sarajevo
Embassy Santo Domingo
Embassy Santiago
Embassy Sanaa
Embassy San Salvador
Embassy San Jose
Consulate Strasbourg
Consulate St Petersburg
Consulate Shenyang
Consulate Shanghai
Consulate Sapporo
Consulate Sao Paulo
Embassy Tunis
Embassy Tripoli
Embassy Tokyo
Embassy The Hague
Embassy Tel Aviv
Embassy Tehran
Embassy Tegucigalpa
Embassy Tbilisi
Embassy Tashkent
Embassy Tallinn
Consulate Toronto
Consulate Tijuana
USUN New York
USEU Brussels
US Office Almaty
US Mission Geneva
US Interests Section Havana
US Delegation, Secretary
UNVIE
Embassy Ulaanbaatar
Embassy Vilnius
Embassy Vienna
Embassy Vatican
Embassy Valletta
Consulate Vladivostok
Consulate Vancouver
Browse by tag
AU
ASEC
AE
AF
AORC
AEMR
AMGT
ABUD
AFFAIRS
APER
AS
AMED
AY
AG
AR
AJ
AL
AID
AM
AODE
ABLD
AMG
AFIN
ATRN
AGAO
AFU
AN
AA
ALOW
APECO
ADM
ARF
ASEAN
APEC
AMBASSADOR
AO
ASUP
AZ
AADP
ACOA
ANET
AMCHAMS
ACABQ
ASECKFRDCVISKIRFPHUMSMIGEG
APCS
AGMT
AINF
AIT
AORL
ACS
AFSI
AFSN
ACBAQ
AFGHANISTAN
ADANA
ADPM
AX
ADCO
AECL
AMEX
ACAO
ASCH
AORG
AGR
AROC
ASIG
AND
ARM
AQ
ATFN
AC
AUC
ASEX
AER
AVERY
AGRICULTURE
BL
BR
BO
BA
BD
BM
BK
BG
BU
BB
BH
BTIO
BY
BEXP
BP
BE
BRUSSELS
BF
BIDEN
BT
BX
BC
BILAT
BN
BBSR
BTIU
BWC
BMGT
CA
CASC
CVIS
CM
CH
CO
CU
CD
CWC
CI
CS
CY
CMGT
CF
CG
CR
CB
CV
CW
CE
CBW
CT
CPAS
COUNTERTERRORISM
CJAN
CODEL
CIDA
CDG
CDC
CIA
CTR
CNARC
CSW
CN
CONS
CLINTON
COE
CROS
CARICOM
CONDOLEEZZA
COUNTER
CL
COM
CICTE
CIS
CFED
COUNTRY
CJUS
CBSA
CEUDA
CLMT
CAC
COPUOS
CIC
CBE
CHR
CTM
CVR
CITEL
CLEARANCE
CACS
CAN
CITT
CARSON
CACM
CDB
CAPC
CKGR
CBC
EC
EG
EPET
ECON
ETRD
EFIN
EIND
EMIN
ENRG
EAID
EAGR
EUN
ETTC
EAIR
ENIV
ES
EU
EINV
ELAB
ECIN
EFIS
ELTN
EWWT
ECPS
ECONOMIC
ENGR
EN
EINT
EPA
ELN
ESA
EZ
ER
ET
EFTA
EINVECONSENVCSJA
EUMEM
ETRA
EXTERNAL
EI
EUR
EK
ERNG
ENGY
ETRDEINVECINPGOVCS
ENERG
EINVEFIN
ENVR
ECA
ELECTIONS
ETC
EUREM
ENNP
EFINECONCS
EURN
ECINECONCS
EEPET
EXIM
ERD
ENVI
ETRC
ETRDEINVTINTCS
ETRO
EDU
ETRN
EAIG
ECONCS
ECONOMICS
EAP
ECONOMY
EINN
EIAR
EXBS
ECUN
EINDETRD
EREL
EUC
ESENV
ECONEFIN
ECIP
EFIM
EAIDS
ETRDECONWTOCS
EUNCH
EINVETC
IZ
IT
IR
IS
IN
IC
IAEA
IO
ICAO
IWC
ID
IV
ISRAEL
IAHRC
IQ
ICTR
IMF
IRS
IDP
IGAD
ICRC
ICTY
IMO
IL
INRA
INRO
ICJ
ITU
IBRD
INMARSAT
IIP
ITALY
IEFIN
IACI
ILO
INTELSAT
ILC
ITRA
IDA
INRB
IRC
INTERPOL
IA
IPR
IRAQI
ISRAELI
INTERNAL
ISLAMISTS
INDO
ITPHUM
ITPGOV
ITALIAN
IBET
INR
IEA
IZPREL
IRAJ
ITF
IF
KDEM
KU
KPAL
KNNP
KCRM
KZ
KN
KS
KJUS
KTFN
KSCA
KV
KISL
KPAO
KPKO
KIRF
KTIA
KIPR
KFLO
KFRD
KTIP
KAWC
KSUM
KCOM
KAID
KE
KTDB
KMDR
KOMC
KWBG
KDRG
KVPR
KTEX
KGIC
KWMN
KSCI
KCOR
KACT
KDDG
KHLS
KSAF
KFLU
KSEO
KMRS
KSPR
KOLY
KSEP
KVIR
KGHG
KIRC
KUNR
KIFR
KCIP
KMCA
KMPI
KBCT
KHSA
KICC
KIDE
KCRS
KMFO
KRVC
KRGY
KR
KAWK
KG
KFIN
KHIV
KBIO
KOCI
KBTR
KNEI
KPOA
KCFE
KPLS
KSTC
KHDP
KPRP
KCRCM
KLIG
KCFC
KTER
KREC
KTBT
KPRV
KSTH
KRIM
KRAD
KWAC
KWMM
KFRDCVISCMGTCASCKOCIASECPHUMSMIGEG
KOMS
KX
KMIG
KRCM
KVRP
KBTS
KPAONZ
KNUC
KNAR
KPWR
KNPP
KDEMAF
KNUP
KNNPMNUC
KERG
KGIT
KPAI
KTLA
KFSC
KCSY
KSAC
KTRD
KID
KOM
KMOC
KJUST
KGCC
KREL
KFRDKIRFCVISCMGTKOCIASECPHUMSMIGEG
KFTFN
KO
KNSD
KHUM
KSEC
KCMR
KCHG
KICA
KPIN
KESS
KDEV
KCGC
KWWMN
KPAK
KWNM
KWMNCS
KRFD
MOPS
MCAP
MPOS
MARR
MO
MNUC
MX
MASS
MG
MY
MU
ML
MR
MILITARY
MTCRE
MT
MEPP
MA
MDC
MP
MAR
MASSMNUC
MARAD
MAPP
MZ
MD
MI
MEETINGS
MK
MCC
MEPN
MRCRE
MAS
MIL
MASC
MC
MV
MTCR
MIK
MUCN
MEDIA
MERCOSUR
MW
MOPPS
MTS
MLS
MILI
MTRE
MEPI
MQADHAFI
MAPS
NO
NATO
NL
NP
NZ
NSF
NI
NH
NG
NAFTA
NU
NASA
NR
NATOPREL
NSSP
NSG
NA
NT
NW
NK
NPT
NPA
NATIONAL
NPG
NSFO
NS
NSC
NE
NGO
NDP
NIPP
NRR
NEW
NZUS
NC
NAR
NV
NORAD
OTRA
OPCW
OVIP
OAS
OREP
OPIC
OIIP
OPRC
ODIP
OEXC
OPDC
OSCE
OIC
OSCI
OECD
OFDP
OFDA
OMIG
OPAD
OFFICIALS
OVP
OIE
OHUM
OCS
OBSP
OTR
OSAC
ON
OCII
OES
PGOV
PREL
PHUM
PTER
PINS
PINR
PREF
PK
PROP
PA
PARM
PBTS
PMAR
PM
PGIV
PE
PRAM
PHUH
PHSA
PL
PNAT
PO
PLN
PAO
PSA
PHUMPGOV
PF
PEL
PBIO
POLITICS
PHUMBA
PAS
POL
PREO
PAHO
PMIL
POGOV
POV
PAK
PNR
PRL
PG
PREFA
PSI
PINL
PU
PARMS
PRGOV
PALESTINIAN
PAIGH
POLITICAL
PARTIES
POSTS
PROG
PORG
PTBS
PUNE
POLICY
PDOV
PCI
PGOVSMIGKCRMKWMNPHUMCVISKFRDCA
PBT
PP
PS
PY
PTERE
PGOF
PKFK
PSOE
PEPR
PPA
PINT
PRELP
PSEPC
PGOVE
PINF
PNG
PGOC
PFOR
PCUL
POLINT
PGGV
PHALANAGE
PARTY
PGOVLO
PHUS
PDEM
PECON
PROV
PHUMPREL
RS
RU
RELATIONS
RW
RO
RM
RP
ROOD
RICE
RUPREL
RSO
RCMP
REACTION
REPORT
REGION
RIGHTS
RF
RFE
RSP
RIGHTSPOLMIL
ROBERT
SU
SCUL
SNAR
SOCI
SF
SA
SHUM
SENV
SP
SR
SY
SANC
SC
SMIG
SZ
SARS
SW
SEVN
SO
SEN
SL
SNARCS
SNARN
SI
SG
SN
SH
SYR
SAARC
SPCE
SHI
SCRS
SENVKGHG
SYRIA
SWE
STEINBERG
SIPRS
ST
SNARIZ
SSA
SK
SPCVIS
SOFA
SIPDIS
SAN
TC
TI
TBIO
TH
TSPL
TRGY
TSPA
TPHY
TU
TW
TS
TAGS
TK
TX
TNGD
TZ
TF
TL
TV
TN
TD
TIP
TR
TP
TO
TT
TFIN
THPY
TERRORISM
TINT
TRSY
TURKEY
TBID
US
UK
UNGA
UP
UZ
UNMIK
USTR
UNO
UNSC
UN
UNESCO
UNAUS
UNHRC
UY
UG
UNHCR
UNCND
USOAS
USEU
UNICEF
UNEP
UV
UNPUOS
UNCSD
USUN
UNCHR
UNDC
USNC
UE
UNDP
UNC
USPS
USAID
UNVIE
UAE
UNFICYP
UNODC
UNCHS
UNIDROIT
UNDESCO
UNCHC
Browse by classification
Community resources
courage is contagious
Viewing cable 06WELLINGTON40, DRUG INDUSTRY SEES POSSIBLE SALVE TO ITS PAIN IN
If you are new to these pages, please read an introduction on the structure of a cable as well as how to discuss them with others. See also the FAQs
Understanding cables
Every cable message consists of three parts:
- The top box shows each cables unique reference number, when and by whom it originally was sent, and what its initial classification was.
- The middle box contains the header information that is associated with the cable. It includes information about the receiver(s) as well as a general subject.
- The bottom box presents the body of the cable. The opening can contain a more specific subject, references to other cables (browse by origin to find them) or additional comment. This is followed by the main contents of the cable: a summary, a collection of specific topics and a comment section.
Discussing cables
If you find meaningful or important information in a cable, please link directly to its unique reference number. Linking to a specific paragraph in the body of a cable is also possible by copying the appropriate link (to be found at theparagraph symbol). Please mark messages for social networking services like Twitter with the hash tags #cablegate and a hash containing the reference ID e.g. #06WELLINGTON40.
Reference ID | Created | Released | Classification | Origin |
---|---|---|---|---|
06WELLINGTON40 | 2006-01-13 05:15 | 2011-04-28 00:00 | CONFIDENTIAL//NOFORN | Embassy Wellington |
VZCZCXYZ0000
RR RUEHWEB
DE RUEHWL #0040/01 0130515
ZNY CCCCC ZZH
R 130515Z JAN 06
FM AMEMBASSY WELLINGTON
TO RUEHC/SECSTATE WASHDC 2273
INFO RUEHBY/AMEMBASSY CANBERRA 4273
RUEHDN/AMCONSUL SYDNEY 0417
RUCPDOC/USDOC WASHDC 0022
C O N F I D E N T I A L WELLINGTON 000040
SIPDIS
SENSITIVE
SIPDIS
DEPARTMENT FOR EAP/ANP-DRICCI AND EB/TPP/BTA/ANA-MBGOODMAN
STATE PASS TO USTR FOR BWEISEL
COMMERCE FOR 4530/ITA/MAC/AP/OSAO/ABENAISSA
E.O. 12958: DECL: 01/12/2016
TAGS: ECON ETRD NZ
SUBJECT: DRUG INDUSTRY SEES POSSIBLE SALVE TO ITS PAIN IN
NEW ZEALAND
REF: A. 05 WELLINGTON 577
¶B. 05 WELLINGTON 119
¶C. 04 WELLINGTON 1037
(U) Classified by Charge d'Affaires David R. Burnett.
Reason: 1.4 (b) and (d).
Summary
-------
¶1. (SBU) The pharmaceutical industry in New Zealand is
enjoying a dose of optimism about the prospect of changes to
the government's drug-purchasing system, which has crimped
the industry for the past 12 years. The government has
promised a review of the system that controls the range and
price of most prescription medicines in New Zealand, at a
time when patient and doctors' attacks on its drug-purchasing
agency have escalated. Nonetheless, most drug companies
continue to believe that only the lure of a free-trade
agreement between New Zealand and the United States would
prompt the New Zealand government to make the changes the
industry contends are needed to assure its long-term
viability in the country.
Pressuring PHARMAC
------------------
¶2. (U) Since 1993, the Pharmaceutical Management Agency
(PHARMAC) has decided which medicines will be subsidized by
the government and how much reimbursement will be paid.
PHARMAC controls the purchase of about 80 percent of
prescription pharmaceuticals in New Zealand. The agency's
aim is to contain pharmaceutical spending, and it has largely
succeeded. While the total number of prescriptions written
for most drugs has risen since 1997, the average price of
prescriptions has decreased, mainly as a result of price
reductions negotiated by PHARMAC with drug manufacturers.
The focus on holding down costs has meant that many
cutting-edge drugs are not subsidized or that manufacturers
withhold certain unsubsidized drugs from the New Zealand
market because their negligible sales discourage efforts to
secure regulatory approval (ref C).
¶3. (U) Over the past year, PHARMAC has come under increased
political criticism, greater scrutiny by the media and
sharper questioning by the public. First, it mishandled the
supply of the nation's influenza vaccine before last winter's
flu season. To secure the best deal, PHARMAC placed its
entire vaccine order with Sanofi Pasteur, which then
encountered a manufacturing problem in late February 2005
that left New Zealand 150,000 doses short. Alternate
suppliers eventually were found, and PHARMAC now insists on
dual sources for vaccines. But the incident highlighted the
agency's common practice of maximizing discounts by
negotiating with a single supplier.
¶4. (U) Patient groups, doctors and the public have become
increasingly vocal about PHARMAC's shortcomings -- a contrast
from past years in which consumers generally believed that if
PHARMAC did not fund a drug, it was not worth having (ref C).
Uppermost in the public's mind is the agency's failure to
fund modern medicines for a range of illnesses including
early stage breast cancer, heart disease, HIV/AIDS and
Alzheimer's. PHARMAC last year backed down from several
decisions that sparked outrage among doctors and patients.
For instance, the agency had hoped to save NZ $1 million (US
$697,300) by halting subsidies for the asthma drug Ventolin
in favor of Salamol, a cheaper substitute. After a public
outcry, PHARMAC announced it would allow patients to choose
either product for a two-year period. In perhaps the most
significant expression of public unhappiness with PHARMAC, 25
non-government health organizations on November 24 launched
the Access to Medicines NGO Coalition, calling for a review
of PHARMAC.
¶5. (U) The past year also has seen a surge in newspaper
articles describing the plight of patients with
life-threatening diseases who were unable to afford
unsubsidized medicines. Professional criticism is also on
the rise. Several cancer specialists told reporters that New
Zealand lagged other Western countries in providing publicly
funded access to the latest cancer drugs. A cardiologist
said doctors increasingly were being forced to treat patients
with outmoded medications. The New Zealand Medical Journal
published a series of case studies criticizing PHARMAC's
practices, including its sole-supply agreements, the
asthma-drug decision and the failure to subsidize certain
medicines.
¶6. (C) These developments provide mounting evidence of eroded
public confidence in PHARMAC, according to Lesley Clarke,
chief executive officer of Researched Medicines Industry
Association of New Zealand (RMI), the industry's trade
association. She also noted that, after the flu-vaccine
debacle, then Minister of Health Annette King acknowledged
for the first time that PHARMAC needed improvement.
Reviewing Pharmac
-----------------
¶7. (U) The Labour government has promised to develop "a
long-term medicines strategy relating to quality
pharmaceutical usage in the health sector including the role
PHARMAC should play in implementing that strategy." Labour
made that commitment as part of its agreement with the United
Future party to form a government after the September 17
elections. The opposition National Party, which created
PHARMAC while in government in 1993, also supports an agency
review.
¶8. (SBU) PHARMAC says it welcomes such a review, which it
hopes will bring about an increase in the budget for drug
purchases. According to Stuart Bruce, the agency's
communications and external relations manager, PHARMAC last
year ordered a review of its decision-making process for
high-cost drugs and expects to consider proposed changes this
year. Bruce said PHARMAC has found it increasingly difficult
to choose between funding expensive drugs for less common
diseases and funding cheaper medicines that help larger
numbers of patients.
¶9. (C) A new health minister, Pete Hodgson, also may portend
a more hospitable environment for the pharmaceutical
industry. According to Clarke of RMI, Hodgson, a former
veterinarian and science teacher, acknowledges a link between
a strong biotechnology sector -- one of the government's top
economic goals -- and research and development funded by the
pharmaceutical industry. Faced with a restrictive business
environment, the industry over the last decade has slashed
its research spending in New Zealand. Hodgson's predecessor,
Annette King, took a different view of the pharmaceutical
industry, telling its representatives that if the industry
disappeared from New Zealand, the country would simply source
its medicines elsewhere.
Industry in flux
----------------
¶10. (C) These potential changes come at a moment when many of
the pharmaceutical firms are reporting that, for the first
time in years, they are not cutting staff. A couple company
chief executives also noted that, for the first time in three
to four years, they have succeeded in getting a new drug
funded -- albeit, at the cost of accepting further reductions
in the subsidized prices of other products. On the other
hand, GlaxoSmithKline (GSK) last year reduced its staff in
New Zealand by 73 percent, to fewer than 15 positions. It
lost to competitor companies in trying to win subsidies for
several of its leading drugs, and a couple of its competitors
say that GSK is paying a price for publicly and aggressively
challenging PHARMAC a couple years ago.
¶11. (C) Many of the pharmaceutical companies believe that
only a U.S. offer of free-trade negotiations would induce the
New Zealand government to consider significant policy changes
that would affect the industry's competitive position. One
company representative cited the government's suspension of a
study on extending the effective patent life for
pharmaceuticals as evidence of the government's decision to
forgo any changes to pharmaceutical policies that might be
used as trade-offs in negotiating a free-trade agreement
(FTA). The industry wants many of the same concessions that
were provided in the Australia-U.S. FTA, particularly
requiring greater transparency in the drug-purchasing
agency's decision-making and the right to appeal its
decisions. In addition, the industry wants a longer
effective patent life for pharmaceuticals and a change in
PHARMAC's reference-pricing practice, or subsidizing a
pharmaceutical at the level of the lowest-priced medicine in
a therapeutic subgroup. The industry wants a commitment to
greater funding of pharmaceutical purchases.
¶12. (C) Meanwhile, a local area working group (LAWG) was
formed last year by eight pharmaceutical companies that are
based in the United States or do business there. The group
includes two companies -- Pfizer and GSK -- that withdrew
from RMI over the past two years in disagreement over RMI's
priorities. The LAWG's professed aim is to work on issues
that might be raised in FTA negotiations and address concerns
beyond just pharmaceuticals, such as investment in research
and development. However, RMI -- which LAWG members said
would continue to serve as the industry's public spokesperson
-- worries that there may not be room for both groups. The
formation of another industry group may give the government
(and PHARMAC) more leverage in playing one company off
another. However, the LAWG's formation also may foreshadow a
more aggressive approach by the industry toward the
government.
Comment
-------
¶13. (C) Notwithstanding U.S. government views on a possible
FTA with New Zealand, post believes that the formation of a
new coalition government provides a timely opportunity to
foster dialogue between the pharmaceutical industry and the
government. Post is working with the British High Commission
to co-host informal meetings between the industry and
government that would aim to reduce the animosity that has
characterized their relations. (The British are assisting us
to prevent the appearance of a U.S.-only initiative.) This
ideally would allow each side to gain a better understanding
of each other and to recognize common goals. The intent is
to supplement the efforts of both RMI and the LAWG.
Burnett